Phase 2 Bipolar Disorder Trial, Recruiting NCT07046494 Sponsor: Rapport Therapeutics Inc. Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 2 Bipolar Disorder Trial, Recruiting

NCT07046494
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with bipolar I disorder (with or without psychotic symptoms), confirmed through a structured clinical interview, including cases where the episode has mixed features (a mix of manic and depressive symptoms).
  • People who have had at least one previous manic episode (with or without psychotic symptoms) that needed treatment, occurring within the last 5 years before the first study visit.

Who may not be able to join:

  • People who have a history of schizophrenia, schizoaffective disorder, major depressive disorder, or a moderate to severe problem with substance or alcohol use, as identified through a structured clinical interview.
  • People who have a history of conditions affecting memory, thinking, or cognition (such as dementia or delirium), or certain personality disorders (including borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder), based on medical history or the opinion of the study investigator. Note: Any other current diagnoses would need to be discussed with the trial's medical team.
  • People who are considered "rapid cyclers," meaning they have had 4 or more separate mood episodes (manic or depressive) in the past 12 months, with each episode fully meeting the clinical diagnostic criteria and separated by at least 2 months of full or partial recovery, or a switch to the opposite type of episode.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Edwin A Gomez, MD, CenExel Research Centers of America

Phone: (857) 323-9048

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Rapport Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
25 July 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Young Mania Rating Scale (YMRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov